机译:肿瘤突变负担标准化举措:临床样本中一致肿瘤突变负担评估的建议,以指导免疫治疗决策
Institute of Pathology University Hospital Heidelberg (on behalf of QuIP? GmbH Berlin Germany;
Science Policy Friends of Cancer ResearchWashington District of Columbia;
Management DepartmentQuIP? GmbHBerlin Germany;
Science Policy Friends of Cancer ResearchWashington District of Columbia;
Science Policy Friends of Cancer ResearchWashington District of Columbia;
Science Policy Friends of Cancer ResearchWashington District of Columbia;
Institute of Pathology Charité Berlin (on behalf of QuIP? GmbH Berlin Germany)Berlin Germany;
biomarkers; immune checkpoint inhibitors; neoantigens; next‐generation sequencing; tumor mutational burden/load;
机译:肿瘤突变负担标准化举措:临床样本中一致肿瘤突变负担评估的建议,以指导免疫治疗决策
机译:NFE2L2 / Keap1 NFE2L2 NFE2L2 / Keap1 Keap1突变与较高的肿瘤突变负荷值/ PD-L1 PD-L1表达和具有免疫疗法的增强改善的临床结果
机译:NFE2L2 / KeaP1突变与肿瘤突变负荷值/ PD-L1表达和PD-L1表达相关,并具有免疫疗法的增强改善的临床结果
机译:使用卷积神经网络从肝癌病理图像预测肿瘤突变负担
机译:Peritumoral水肿与脑膜瘤中的突变负担相关联
机译:肿瘤突变负担标准化举措:关于在临床样本中进行一致的肿瘤突变负担评估的建议以指导免疫疗法的治疗决策
机译:用下一代测序癌基因面板评估非小细胞肺癌患者免疫疗法的血肿突变负担的评估